AbCellera Biologics Inc.

NasdaqGS ABCL

AbCellera Biologics Inc. Operating Income for the year ending December 31, 2023: USD -237.21 M

AbCellera Biologics Inc. Operating Income is USD -237.21 M for the year ending December 31, 2023, a -209.56% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

AbCellera Biologics Inc. Operating Income for the year ending December 31, 2022 was USD 216.51 M, a 5.92% change year over year.
AbCellera Biologics Inc. Operating Income for the year ending December 31, 2021 was USD 204.41 M, a 31.01% change year over year.
AbCellera Biologics Inc. Operating Income for the year ending December 31, 2020 was USD 156.03 M, a 3,889.91% change year over year.
AbCellera Biologics Inc. Operating Income for the year ending December 31, 2019 was USD -4.12 M, a -446.75% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGS: ABCL

AbCellera Biologics Inc.

CEO	Dr. Carl L.G. Hansen Ph.D.
IPO Date	Dec. 11, 2020
Location	Canada
Headquarters	2215 Yukon Street
Employees	586
Sector	Health Care
Industries Biotechnology Artificial Intelligence (AI) Pharmaceuticals

Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Key trends

Past 5 years